Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model
Abstract Phosphodiesterase (PDE) 4 inhibitors have been reported to suppress the progression of dermal fibrosis in patients with systemic sclerosis (SSc); however, the precise mechanisms remain to be elucidated. Therefore, we conducted experiments focusing on the antifibrotic and anti-inflammatory e...
Main Authors: | Tomoaki Higuchi, Kae Takagi, Akiko Tochimoto, Yuki Ichimura, Hikaru Hirose, Tatsuo Sawada, Noriyuki Shibata, Masayoshi Harigai, Yasushi Kawaguchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-46737-1 |
Similar Items
-
Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment
by: Tomoaki Higuchi, et al.
Published: (2019-04-01) -
Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
by: Yang Miao, et al.
Published: (2023-03-01) -
Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Hanjing Sheng, et al.
Published: (2022-06-01) -
Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Xiaohe Li, et al.
Published: (2019-09-01) -
Anti-Inflammatory and Antifibrotic Potential of Longidaze in Bleomycin-Induced Pulmonary Fibrosis
by: Angelina Pakhomova, et al.
Published: (2023-09-01)